- Earlier in May 2026, Revvity, Inc. reported first-quarter sales of US$711.12 million and updated its full-year 2026 revenue outlook to US$2.81–US$2.84 billion, while its Immunodiagnostic Systems unit secured FDA clearance for a Total Testosterone automated chemiluminescence immunoassay.
- By pairing stronger-than-anticipated operating performance with an expanded endocrine and reproductive health testing menu, Revvity is reinforcing its position across both life sciences tools and diagnostics customers.
- We’ll now examine how Revvity’s stronger-than-expected first-quarter performance could influence the existing investment narrative around its earnings power.
Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
Revvity Investment Narrative Recap
To be a Revvity shareholder today, you need to believe the company can balance steady, if modest, top line growth with a shift toward higher margin software, consumables, and specialized diagnostics. The stronger first quarter, coupled with a slightly lower full year revenue outlook versus earlier guidance, modestly supports the near term earnings power story, but does not fully offset key risks around reimbursement pressure in China and ongoing funding weakness in academic and government end markets.
Among the latest developments, the FDA clearance for Immunodiagnostic Systems’ Total Testosterone assay looks most relevant, as it expands Revvity’s endocrine and reproductive health offering on a single automated platform. This fits directly with one of the core catalysts for the stock: growing demand for advanced diagnostics and reproductive health testing, which can deepen recurring consumables revenue and support the margin mix, even as legacy multiplex diagnostics and China exposure remain under pressure.
Yet against this progress, investors should still be aware of how fast changing Chinese DRG policies could reshape high margin diagnostics volumes and...
Read the full narrative on Revvity (it's free!)
Revvity’s narrative projects $3.3 billion revenue and $599.9 million earnings by 2028. This requires 5.4% yearly revenue growth and a $321.2 million earnings increase from $278.7 million today.
Uncover how Revvity's forecasts yield a $119.56 fair value, a 27% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were assuming revenue of about US$3.4 billion and earnings near US$685 million by 2029, which looks far more bullish than the baseline view that highlights regulatory and pricing pressures; after this quarter’s update and the new testosterone assay clearance, you may see those optimistic and cautious narratives shift again in different directions.
Explore 2 other fair value estimates on Revvity - why the stock might be worth as much as 47% more than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Revvity research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Revvity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revvity's overall financial health at a glance.
Seeking Other Investments?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- Find 51 companies with promising cash flow potential yet trading below their fair value.
- We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The latest GPUs need a type of rare earth metal called Dysprosium and there are only 30 companies in the world exploring or producing it. Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com